Regulatory News - Americas

April 10, 2018 / 9:38 AM / 3 months ago

BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease

Reuters Staff

1 Min Read

April 10 (Reuters) - GB Sciences Inc:

* BASED THERAPY FOR PARKINSON’S DISEASE

* EXPECTS TO COMMENCE ITS FIRST-IN-HUMAN TRIAL IN EARLY 2019

* COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below